Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Perspective Therapeutics, Inc. (CATX) reported an administrative update: the company updated its corporate presentation. The presentation was furnished under Item 8.01 and attached as Exhibit 99.1, dated November 6, 2025.
Perspective Therapeutics (CATX) amended and restated employment agreements for its CEO Johan (Thijs) Spoor, Chief Accounting Officer Jonathan Hunt, and Chief Medical Officer Dr. Markus Puhlmann. The updates reflect current base salaries and revise change-in-control provisions.
Base salaries are $680,000 for Mr. Spoor, $451,500 for Mr. Hunt, and $516,700 for Dr. Puhlmann. If employment ends without cause or for good reason during the three months before or 12 months after a change in control, severance includes salary continuation for 12 months (18 months for Mr. Spoor), a pro‑rated target bonus, an additional amount equal to the target bonus (1.5x target for Mr. Spoor), and COBRA premiums for up to 12 months (18 months for Mr. Spoor).
Equity awards subject to time-based vesting accelerate to full vesting, and performance-based awards vest at target upon qualifying terminations in the protection period or if awards are not assumed, replaced, or continued at closing, subject to a release of claims. Other existing terms remain in effect.
Perspective Therapeutics (CATX) filed an 8‑K announcing a press release and presentation with updated interim results from its Phase 1/2a study of [212Pb]VMT‑α‑NET in patients with unresectable or metastatic SSTR2‑expressing neuroendocrine tumors. The data are being presented at ESMO 2025 in Berlin. The materials also include the Company’s estimated cash, cash equivalents and short‑term investments as of September 30, 2025, which are preliminary, unaudited, and subject to change.
Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation. The updated presentation, dated October 1, 2025, is furnished as Exhibit 99.1 to the report and incorporated by reference into the other events section.
Perspective Therapeutics insider Joel Sendek, the company's Chief Financial Officer, was granted a stock option on 09/04/2025 to purchase 600,000 shares of common stock at an exercise price of $3.54 per share. The option has an expiration date of 09/04/2035 and becomes exercisable over a four-year vesting schedule: one-fourth vests on 09/04/2026 and the remaining shares vest ratably over the following 36 months, subject to continuous service. After the grant, the reporting person beneficially owns 600,000 underlying shares through the option, held in a direct ownership form. The Form 4 was signed by attorney-in-fact on 09/05/2025.
Joel Sendek, serving as Chief Financial Officer and a director of Perspective Therapeutics, Inc. (CATX), filed an initial Form 3 reporting the 09/04/2025 event date. The filing states that the reporting person does not beneficially own any securities of the issuer. The form references Exhibit 24 (Power of Attorney) and was signed via attorney-in-fact on 09/05/2025.
Maria E. Martinez, a director of Perspective Therapeutics, Inc. (CATX), was granted 75,000 stock options on 09/03/2025 with an exercise price of $3.38. The options vest monthly over three years in 36 substantially equal installments beginning one month after the grant date, are exercisable beginning 09/03/2025, and expire on 09/03/2035. After the reported transaction the reporting person beneficially owns 75,000 shares underlying the option on a direct basis. The Form 4 was signed on behalf of Maria E. Martinez by an attorney-in-fact on 09/05/2025.
Perspective Therapeutics, Inc. (CATX) filed a Form 3 reporting Maria E. Martinez as a Director and a reporting person. The event date listed is 09/03/2025. The filing states explicitly that no securities are beneficially owned by the reporting person and references Exhibit 24 (Power of Attorney). The form is signed by Maria E. Martinez via attorney-in-fact on 09/05/2025.
Perspective Therapeutics, Inc. appointed Joel Sendek as its new Chief Financial Officer and principal financial officer, effective September 4, 2025, replacing Juan Graham in the CFO role. The company detailed Mr. Sendek’s background, compensation, equity incentives, and severance protections in his employment agreement.
Mr. Sendek will receive a $500,000 annual base salary, a target annual bonus equal to 40% of base salary, and a one-time option grant to purchase 600,000 shares of common stock, vesting over four years. The agreement also provides 12 months of salary, bonus-related amounts, COBRA premiums, and accelerated vesting of equity awards under certain termination and change-in-control conditions, subject to a release of claims.
Perspective Therapeutics, Inc. reported that its Board of Directors voted to increase the board size from five to six members and appointed Maya Martinez-Davis as a director, effective September 3, 2025. She will also serve on the Compensation Committee and the Nominations and Corporate Governance Committee.
Under the company’s Non-Employee Director Compensation Program, Ms. Martinez-Davis will receive an annual cash retainer of $60,000 and an initial grant of 75,000 stock options, with the grant date fair value capped at $450,000. These options vest in 36 equal monthly installments starting one month after the grant date, contingent on her continued service. The company expects her to enter into its standard indemnification agreement, and it states there are no related-party transactions requiring disclosure. A press release announcing her appointment was issued on September 3, 2025 and furnished as Exhibit 99.1.